<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1055</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2025-20-3-76-83</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CURRENT BASIC RESEARCH IN HEMATOLOGY AND PRACTICAL MEDICINE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ОНКОГЕМАТОЛОГИИ И ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Features of the subpopulation composition and functional activity of peripheral blood lymphocytes and monocytes in patients with primary autoimmune thrombocytopenia</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности субпопуляционного состава и функциональной активности лимфоцитов и моноцитов периферической крови у больных первичной аутоиммунной тромбоцитопенией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4393-1759</contrib-id><name-alternatives><name xml:lang="en"><surname>Chuksina</surname><given-names>Yu. Yu.</given-names></name><name xml:lang="ru"><surname>Чуксина</surname><given-names>Ю. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Yulia Yuryevna Chuksina</p><p>61 / 2 Shchepkina St., Moscow 129110</p></bio><bio xml:lang="ru"><p>Юлия Юрьевна Чуксина</p><p>129110 Москва, ул. Щепкина, 61 / 2</p></bio><email>tchuxina2009@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2847-4374</contrib-id><name-alternatives><name xml:lang="en"><surname>Zakharov</surname><given-names>S. G.</given-names></name><name xml:lang="ru"><surname>Захаров</surname><given-names>С. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>61 / 2 Shchepkina St., Moscow 129110</p></bio><bio xml:lang="ru"><p>129110 Москва, ул. Щепкина, 61 / 2</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7493-0030</contrib-id><name-alternatives><name xml:lang="en"><surname>Mitina</surname><given-names>T. A.</given-names></name><name xml:lang="ru"><surname>Митина</surname><given-names>Т. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>61 / 2 Shchepkina St., Moscow 129110</p></bio><bio xml:lang="ru"><p>129110 Москва, ул. Щепкина, 61 / 2</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">M. F. Vladimirskiy Moscow Regional Research Clinical Institute</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-09-11" publication-format="electronic"><day>11</day><month>09</month><year>2025</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>76</fpage><lpage>83</lpage><history><date date-type="received" iso-8601-date="2025-09-11"><day>11</day><month>09</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-09-11"><day>11</day><month>09</month><year>2025</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/1055">https://oncohematology.abvpress.ru/ongm/article/view/1055</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. Primary immune thrombocytopenia (ITP) is an immune-mediated disease characterized by platelet destruction and impaired thrombopoiesis with the development of varying severity hemorrhagic syndrome. The first line of therapy for ITP patients are glucocorticosteroids, which have limited efficacy and frequent complications. Factors of innate and adaptive immunity play a key role in ITP pathogenesis, the study of which is especially relevant for assessing the immunological reactivity of patients and substantiating new therapeutic approaches in real clinical practice.<bold>Aim</bold>. To evaluate the characteristics of the subpopulation composition and functional activity of peripheral blood lymphocytes and monocytes in ITP patients and to identify possible immunological prognostic criteria for the disease course and resistance to glucocorticosteroid therapy.Materials and methods. In 20 patients with newly diagnosed ITP and in 20 ITP patients with resistance to glucocorticosteroid therapy, the relative and absolute parameters of T-lymphocytes (CD3+), B-lymphocytes (CD19+), NK cells (CD3–CD16+CD56+), T-helper cells (CD3+CD4+), T-cytotoxic (CD3+CD8+) and NKT (CD3+CD16+CD56+) subpopulations of peripheral blood lymphocytes, as well as the expression of HLA-DR on lymphocytes and monocytes, CD25 on CD4+ T-lymphocytes and CD40 on B -lymphocytes were analyzed using flow cytometry. Thirty healthy individuals were examined as a control group.<bold>Results</bold>. In patients with newly diagnosed ITP, a sharp decrease in the absolute number of B cells and T-helper lymphocytes in peripheral blood was observed, and pronounced activation of T-lymphocytes by HLA-DR expression and B-lymphocytes by costimulatory molecule CD40 expression was noted. In patients with glucocorticosteroids resistance, a significant decrease in the absolute number of peripheral blood T-helper lymphocytes, an increase in the content of activated CD3+HLA-DR+ lymphocytes were also detected, but the level of CD40+ B-lymphocytes was reduced compared to primary patients.In patients of both groups, a significant (p &lt;0.001) decrease in HLA-DR mean fluorescence intensity on peripheral blood monocytes was detected, which may indicate an insufficient ability of monocytes and macrophages to effectively antigen processing.<bold>Conclusion</bold>. Patients with ITP have been found to have significant disturbances in the quantitative parameters of cellular adaptive immunity and the functional activity of peripheral blood lymphocytes and monocytes, which play an important role in the immunopathogenesis of the disease.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Первичная иммунная тромбоцитопения (ИТП) – иммуноопосредованное заболевание, характеризующееся деструкцией тромбоцитов и нарушением тромбоцитопоэза с развитием геморрагического синдрома различной степени выраженности. Первой линией терапии больных ИТП являются глюкокортикостероидные препараты, характеризующиеся ограниченной эффективностью и частыми осложнениями. Ключевую роль в патогенезе ИТП играют факторы врожденного и адаптивного иммунитета, изучение которых особенно актуально для оценки иммунологической реактивности пациентов и обоснования новых терапевтических подходов в реальной клинической практике.<bold>Цель исследования</bold> – оценить особенности субпопуляционного состава и функциональной активности лимфоцитов и моноцитов периферической крови у больных ИТП и выявить возможные иммунологические прогностические критерии течения заболевания и резистентности к терапии глюкокортикостероидными препаратами.<bold>Материалы и методы</bold>. У 20 пациентов с впервые выявленной ИТП и у 20 больных ИТП с резистентностью к терапии глюкокортикостероидными препаратами проанализированы относительные и абсолютные параметры Т-лимфоцитов (CD3+), В-лимфоцитов (CD19+), NK-клеток (CD3–CD16+CD56+), Т-хелперной (CD3+CD4+), Т-цитотоксической (CD3+CD8+) и NKT (CD3+CD16+CD56+) субпопуляций лимфоцитов периферической крови, а также экспрессии HLA-DR на лимфоцитах и моноцитах, CD25 на CD4+ Т-лимфоцитах и CD40 на В-лимфоцитах методом проточной цитометрии. В качестве контрольной группы обследованы 30 практически здоровых лиц.<bold>Результаты</bold>. У пациентов с впервые выявленной ИТП наблюдалось резкое снижение абсолютного числа В-клеток и Т-хелперных лимфоцитов периферической крови, отмечена выраженная активация Т-лимфоцитов по экспрессии HLA-DR-антигена и В-лимфоцитов по экспрессии костимулирующей молекулы CD40. У пациентов с резистентностью к глюкокортикостероидным препаратам также выявлены значимое снижение абсолютного числа Т-хелперных лимфоцитов периферической крови, увеличение содержания активированных CD3+HLA-DR+-лимфоцитов, но уровень CD40+-В-лимфоцитов был снижен по сравнению с первичными пациентами.У пациентов обеих групп выявлено значительное (p &lt;0,001) снижение показателя средней интенсивности флуоресценции HLA-DR на моноцитах периферической крови, что может свидетельствовать о недостаточной способности моноцитарно-макрофагального звена к эффективному процессингу антигена.<bold>Заключение</bold>. У больных ИТП выявлены выраженные нарушения количественных параметров клеточного адаптивного иммунитета и функциональной активности лимфоцитов и моноцитов периферической крови, играющие важную роль в иммунопатогенезе заболевания.</p></trans-abstract><kwd-group xml:lang="en"><kwd>immune thrombocytopenia</kwd><kwd>innate and adaptive immunity</kwd><kwd>CD40 costimulatory molecule</kwd><kwd>flow cytometry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>иммунная тромбоцитопения</kwd><kwd>врожденный и адаптивный иммунитет</kwd><kwd>костимулирующая молекула CD40</kwd><kwd>проточная цитометрия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Clinical recommendations. Idiopathic thrombocytopenic purpura (ITP) in adults. 2021. Available at: https://cr.minzdrav.gov.ru/schema/150_2 (accessed 04.02.2024). (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Клинические рекомендации. Идиопатическая тромбоцитопеническая пурпура (ИТП) у взрослых. 2021. Доступно по: https://cr.minzdrav.gov.ru/schema/150_2 (дата обращения: 04.02.2024).</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kovaleva L.G., Pustovaya E.I., Safonova T.I. Idiopathic thrombocytopenic purpura (ITP) of adults. Primary immune thrombocytopenia (ITP) in adults. Werlhof’s disease. Moscow: Gematologicheskiy nauchniy tsentr, 2014. 131 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Ковалева Л.Г., Пустовая Е.И., Сафонова Т.И. Идиопатическая тромбоцитопеническая пурпура (ИТП) взрослых. Первичная иммунная тромбоцитопения (ИТП) взрослых. Болезнь Верльгофа. М.: Гематологический научный центр, 2014. 131 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Provan D., Arnold D., Bussel J.B. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22):3780–808. DOI: 10.1182/bloodadvances-2019000812</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zhao C., Li X., Zhang F. et al. Increased cytotoxic T-lymphocytemediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008;93(9):1428–30. DOI: 10.3324/haematol.12889</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia. Presse Med 2014;43(4 Pt 2):e49–59. DOI: 10.1016/j.lpm.2014.01.010</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ogawara H., Handa H., Morita K. et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003;71(4):283–8. DOI: 10.1034/j.1600-0609.2003. 00138.x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wang T., Zhao H., Ren H. et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005;90(7):914–23.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Guo Z.X., Chen Z.P., Zheng C.L. et al. The role of Th17 cells in adult patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2009;82(6):488–9. DOI: 10.1111/j.1600-0609.2009.01229.x</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zhang J., Ma D., Zhu X. et al. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 2009;94(9):1326–9. DOI: 10.3324/haematol.2009.007823</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cao J., Chen C., Zeng L. et al. Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia. Clin Immunol 2011;141(1):121–3. DOI: 10.1016/j.clim.2011. 05.003</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hu Y., Li H., Zhang L. et al. Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum Immunol 2012;73(6):629–35. DOI: 10.1016/j.humimm.2012. 04.015</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Audia S., Rossato M., Santegoets K. et al. Splenic TFH expansion participates in B-cell differentiation and antiplate-let-antibody production during immune thrombocytopenia. Blood 2014;124(18):2858–66. DOI: 10.1182/blood-2014-03-563445</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zhong H., Bao W., Li X. et al. CD16+ monocytes control T-cell subset development in immune thrombocytopenia. Blood 2012;120(16):3326–35. DOI: 10.1182/blood-2012-06-434605</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Semple J.W., Bruce S., Freedman J. Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura. Am J Hematol 1991;37(4):258–62. DOI: 10.1002/ajh.2830370409</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Garcia-Suarez J., Prieto A., Reyes E. et al. Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+CD3– natural killer cells subset. Blood 1993;82(5):1538–45.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ebbo M., Audonnet S., Grados A. et al. NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia. Clin Immunol 2017;177:18–28. DOI: 10.1016/j.clim.2015.11.005</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Olsson B., Andersson P.O., Jernas M. et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9(9):1123–4. DOI: 10.1038/nm921</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kuter D.J. The treatment of immune thrombocytopenia (ITP) – focus on thrombopoietin receptor agonists. Ann Blood 2021;6(7):1–21. DOI: 10.21037/aob-21-23</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zufferey A., Kapur R., Semple J.W. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 2017;6(2):16. DOI: 10.3390/jcm6020016</mixed-citation></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Zakharov S.G., Mitina T.A., Zakharova A.V. et al. Glucocorticosteroid-induced complications in patients with idiopathic thrombocytopenic purpura. Onkogematologiya = Oncohematology 2023;18(4):233–43. (In Russ.). DOI: 10.17650/1818‑8346‑2023‑18‑4‑233‑243</mixed-citation><mixed-citation xml:lang="ru">Захаров С.Г., Митина Т.А., Захарова А.В. и др. Осложнения терапии глюкокортикостероидами у пациентов с идиопатической тромбоцитопенической пурпурой. Онкогематология 2023;18(4):233–43. DOI: 10.17650/1818‑8346‑2023‑18‑4‑233‑243</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Yadgarov M.Ya., Kuzovlev A.N., Berikashvili L.B. et al. Importance of data distribution normality test: theory and practical guide. Anesteziologiya i reanimatologiya = Russian Journal of Anaesthesiology and Reanimatology 2021;(2):136–42. (In Russ.). DOI: 10.17116/anaesthesiology2021021136</mixed-citation><mixed-citation xml:lang="ru">Ядгаров М.Я., Кузовлев А.Н., Берикашвили Л.Б. и др. Важность оценки закона распределения данных: теория и практическое руководство. Анестезиология и реаниматология 2021;(2):136–42. DOI: 10.17116/anaesthesiology2021021136</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Ярилин А.А. Иммунология. М.: ГЭОТАР-Медиа, 2010. С. 452 Yarilin A.A. Immunology. Moscow: GEOTAR-Media, 2010. P. 452. (In Russ.).</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–35. DOI: 10.1146/annurev.immunol.16.1.111</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Koupenova M., Clancy L., Corkrey H.A., Freedman J.E. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res 2018;122(2):337–51. DOI: 10.1161/CIRCRESAHA.117.310795</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Frelinger A.L. 3rd, Grace R.F., Gerrits A.J. et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood 2015;126(7):873–9. DOI: 10.1182/ blood-2015-02-628461</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Kuwana M., Nomura S., Fujimura K. et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004;103(4):1229–36. DOI: 10.1182/ blood-2003-06-2167</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Kuwana M., Kawakami Y., Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood 2003;101(2):621–3. DOI: 10.1182/blood-2002-07-2157</mixed-citation></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Chuksina Yu.Yu., Zakharov S.G., Mitina T.A., Khmelevskaya A.N. Clinical and prognostic significance of T-regulatory cells and CD28 expression on T-lymphocytes in patients with immune thrombocytopenia. Onkogematologiya = Oncohematology 2024;19(4):108–14. (In Russ.). DOI: 10.17650/1818-8346-2024-19-4-108-114</mixed-citation><mixed-citation xml:lang="ru">Чуксина Ю.Ю., Захаров С.Г., Митина Т.А., Хмелевская А.Н. Клинико-прогностическая значимость Т-регуляторных клеток и экспрессии CD28 на Т-лимфоцитах у больных иммунной тромбоцитопенией. Онкогематология 2024;19(4):108–14. DOI: 10.17650/1818-8346-2024-19-4-108-114</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Khaidukov S.V., Zurochka A.V., Chereshnev V.A. Cytometric analysis in clinical immunology. Ekaterinburg: Ural Branch of the Russian Academy of Sciences, 2011. Vol. 4. P. 220. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Хайдуков С.В., Зурочка А.В., Черешнев В.А. Цитометрический анализ в клинической иммунологии. Екатеринбург: УрО РАН, 2011. Т. 4. C. 220.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Klochkova-Abelyants S.A., Surzhikova G.S. Expression of HLA-DR antigens on peripheral blood monocytes as an indicator of the state of the immune system in hypochromic anemia. Politravma = Polytrauma 2012;2:59–67. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Клочкова-Абельянц С.А., Суржикова Г.С. Экспрессия HLA-DR-антигенов на моноцитах периферической крови как показатель состояния иммунной системы при гипохромной анемии. Политравма 2012;2:59–67.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Zurochka A.V., Kotlyarov A.N., Kuvaytsev M.V. et al. Changes of HLA-DR antigen expression on monocytes in children and their clinical significance in sepsis. Meditsinskaya immunologiya = Medical Immunology (Russia) 2008;10(4–5):379–87. (In Russ.). DOI: 10.15789/1563-0625-2008-4-5-379-388</mixed-citation><mixed-citation xml:lang="ru">Зурочка А.В., Котляров А.Н., Кувайцев М.В. и др. Изменения экспрессии HLA-DR-антигенов на моноцитах у детей и ее клиническая значимость при сепсисе. Медицинская иммунология 2008;10(4–5):379–87. DOI: 10.15789/1563-0625-2008-4-5-379-388</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><mixed-citation>Strohmeyer J.C., Blume C., Meisel C. et al. Standardized immune monitoring for the prediction of infections after cardiopulmonary bypass surgery in risk patients. Cytometry 2003;53(1):54–62. DOI: 10.1002/cyto.b.10031</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Hoffman J.A., Weinberg K.I., Azen C.G. et al. Human leukocyte antigen-DR expression on peripheral blood monocytes and the risk of pneumonia in pediatric lung transplant recipients. Transpl Infect Dis 2004;6(4):147–55. DOI: 10.1111/j.1399-3062.2004.00069.x</mixed-citation></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Chuksina Yu.Yu., Moskalets O.V., Yazdovsky V.V. et al. Clinical and immunological parallels in periprosthetic infection after total large joints arthroplasty. Kazanskiy meditsinskiy zhurnal = Kazan Medical Journal 2016;97(4):514–8. (In Russ.). DOI: 10.17750/KMJ2016-514</mixed-citation><mixed-citation xml:lang="ru">Чуксина Ю.Ю., Москалец О.В., Яздовский В.В. и др. Клинико-иммунологические параллели при перипротезной инфекции после тотального эндопротезирования крупных суставов. Казанский медицинский журнал 2016;97(4):514–8. DOI: 10.17750/KMJ2016-514</mixed-citation></citation-alternatives></ref></ref-list></back></article>
